News

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.
The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...
Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...
The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...
Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...
By Sriparna Roy (Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access ...
Citing JPMorgan analysts Reuters report added that Merck KGaA’s oncology business, making up about 25% of its healthcare sales in 2024, could benefit from acquiring SpringWorks.
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will ...
In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and SpringWorks Therapeutics, Inc., a Stamford, Connecticut- based commercial-stage biopharmaceutical company focused on ...